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It rates that in 2030, the cardiovascular diseases (CVD) will result in 40% of all deaths and rank as the leading
cause. Thus, the research of appropriate therapies able to delay or retard their onset and progression is growing.
Of particular interest is a new branch of the medical science, called anti-ageing medicine since CVD are the result of
cardiovascular ageing. Senescent cells (SC) accumulate in cardiovascular system contributing to the onset of
typical age-related cardiovascular conditions (i.e., atherosclerosis, medial aorta degeneration, vascular remod-
eling, stiffness). Such conditions progress in cardiovascular pathologies (i.e., heart failure, coronary artery disease,
myocardial infarction, and aneurysms) by evocating the production of a proinflammatory and profibrotic
senescence-associated secretory phenotype (SASP). Consequently, therapies able to specifically eliminate SC are
in developing. The senotherapeutics represents an emerging anti-SC treatment, and comprises three therapeutic
approaches: (a) molecules to selectively kill SC, defined senolytics; (b) compounds able in reducing evocated SC
SASP, acting hence as SASP suppressors, or capable to change the senescent phenotype, called senomorphics; (c)
inhibition of increase of the number of SC in the tissues. Here, it describes them and the emerging data about
current investigations on their potential clinical application in CVD, stressing benefits and limitations, and sug-
gesting potential solutions for applying them in near future as effective anti-CVD treatments.1. Introduction
Elderly people have shown a rapid boost in Western populations
parallelly to constant increase of life expectancy, even if not inevitably
linked to an equivalent improvement of health (Lunenfeld and Stratton,
2013). Accordingly, ageing populations phenomenon is significantly
associated with the onset of several chronic inflammatory diseases,
described as age-related disease (ARD), including cardiovascular diseases
(CVD), type 2 diabetes (T2D), osteoporosis, neurodegenerative diseases,
and cancer (Edwards, 2012) (Fig. 1A). It rates that in 2030, among ARD,
the CVD will result in 40% of all deaths and rank as the leading cause
(Kirkwood, 2017; Jones et al., 2019). Consequently, the governments
and scientific community are investigating fitting heath actions,
including disease-prevention and health-promotion programs for tar-
geting the major causes of morbidity and mortality in the agedne, Neuroscience, and Advanced D
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evier B.V. This is an open access apopulation, and reducing the cost pressure related to ARD management
and disability (Zolotor and Yorkery, 2019). In this context, promising
appears the emerging anti-ageing medicine, a branch of medical science,
(see Fig. 1B), which is getting a particular attention in the recent decades
(Kirkland, 2013; Flatt et al., 2013; Lopreite and Mauro, 2017). The
anti-ageing medicine intends to promote health-span and lifespan by
employing specific nutritional and physical activity schemes, and
applying biomedical interventions aimed at delaying or reversing the
ageing process (Lemaître et al., 2015; da Costa et al., 2016; Lara et al.,
2016). Furthermore, conventional and alternative medical specialties are
used for designing an interconnected approach with the objective to
achieve the best probable anti-ageing effect in individuals affected by
ARD. Thereby, anti-ageing medicine is a holistic discipline based on the
concept of disease as pathological condition affecting the entire body and
not simply a part. Diverse organizations (e.g. the predominant is theiagnostics (Bi.N.D.), University of Palermo, Corso Tukory, 211, 90134, Palermo,
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Fig. 1A. The strict relationship between aging
and the onset of age-related diseases and the use
of antiaging medicine as solution. With
advancing time, the cells decrease their activity
and show diverse alterations (i.e., including
genomic instability, epigenetic deregulation, loss
of proteostasis, mitochondrial dysfunction, telo-
mere shortening, autophagy, impaired stress
resistance and deregulated nutrient signaling).
This results in the accumulation of damages that
lead the cells in senescence/apoptosis and death.
As result, their senescence or apoptosis occur, as
well as the decline in their ability to be replaced
because of exhaustion of stem cells. This de-
termines an alteration of both homeostasis and
function of tissues, organs, and systems, and the
evocation of inflammation, fibrosis and progres-
sively to the onset of age-related diseases.
Fig. 1B. The antiaging medicine and its potential applications.
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across the globe are proposing courses to physicians, having the interest
in gathering a deep information on anti-ageing medicine and its potential
intervention measures principally versus those with prevention character
of diseases in order to reduce ARD prevalence and incidence and
slow-down their estimated trend. Such results both in advances in the
scientific knowledge and in creating an important platform of informa-
tion for all the individuals of any age-range of a population, providing a
novel perception about the most suitable life behaviours compatible to
extend life span and tackling ageing. In addition, anti-ageing medicine
offers a new idea on the ageing process, considering it a reversible phe-
nomenon (Lemaître et al., 2015). Consequently, some recent theories2
propose that ageing occurs as consequence from other life processes,
apparently having any specific function (Anton et al., 2005). This concept
may appear extreme, but the idea, to manipulate ageing as other
non-fundamental life's processes, increases. Consequently,
age-associated senescence may appear as a complex of pathophysiolog-
ical processes that could be prevented, delayed, or even reversed
(Balistreri, 2018; Balistreri et al., 2020; Vaiserman et al., 2019). At pre-
sent, novel biotechnologies, particularly including omics procedures (i.e.,
genomics, transcriptomics, proteomics, and metabolomics) have emer-
gently applied in the research and potentially result capable to
slow-down or postpone processes related to ageing, and consequently to
be widely applied in anti-ageing medicine (Balistreri, 2018; Balistreri
et al., 2020; Vaiserman et al., 2019). On the other hand, such
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mechanisms related to ageing process, including genomic instability,
epigenetic deregulation, loss of proteostasis, mitochondrial dysfunction,
cellular senescence, exhaustion of stem cells, inflammation, telomere
shortening, autophagy, impaired stress resistance and deregulated
nutrient signaling (Balistreri, 2018; Balistreri et al., 2020; Vaiserman
et al., 2019). This knowledge represents an initial point for developing
innovative therapeutical strategies against the age-related functional
decline and onset of pathological conditions of tissues, organs, and sys-
tems of an organism. Here, we report and discuss new concepts related to
use of senotherapeutics.
1.1. Senescent cells as target for the treatment of ARD
Cellular senescence, and the consequent senescent cells (SC), are the
typical features of ageing process, that arise from a complex number of
cellular and molecular-induced processes (Olivieri et al., 2018; Childs
et al., 2017). Mounting evidence reports such contribution of SC in
determining the aged phenotype (Balistreri, 2018). However, the related
mechanisms have not been fully elucidated, as well as the effective SC
relationship with onset of human ARD. Certainly, a limiting factor, that
has likely contributed to delay the detection of SC in humans, is the
absence to date of standardized biomarkers of senescence in vivo. How-
ever, growing literature reports that SC induce harmful effects on the
tissue microenvironment, by evocating the release of molecules acting as
pathological facilitators or aggravators (amply quoted in Balistreri et al.,
2013). Accordingly, SC contribute to ageing and ARD onset via the sen-
escence-associated secretory phenotype (SASP), which consists in a variety
of soluble factors, including proinflammatory mediators and
matrix-degrading molecules. In tun, SASP contributes to evocate a state
of chronic, systemic, low-grade inflammation, termed inflammageing, one
of the principal risk factors related to the onset of the major ARDs. The
percentage of the proinflammatory level necessary for achieving the
condition over which diseases/disabilities arise, depends on genetic,
environmental, and stochastic factors (Balistreri et al., 2013; Ovadya and
Krizhanovsky, 2014). In turn, the age-related SC accumulation stimulates
the immune system activation, and subsequently determines a conse-
quent chronic immune condition that is closely related to a decreased SC
clearance. Consequently, this continuous immune response and the
related vicious circle generate inflammageing. Beyond immune cells and
tissue cells, also adult stem cells from aged humans are also affected
(mesenchymal stem cells included). Such evidences the capacity of a
senescent milieu in reducing the stemness properties (Hall et al., 2016) or
the differentiation capacity (Liu et al., 2017). At the same time, such
underlines the actions and various characteristics of SASP in the different
tissues.
Altogether, the observations above-described underline that the
accumulation of SC in the tissues is responsible of inflammageing during
ageing maintained by SASP itself (disseminating in blood circulation)
and SASP mediated effects (Weilner et al., 2016a). Relevantly, SC are
present in significant augments in all the tissues, organs, and systems
where ARD occur. Precisely, they are abundant not only in tumors but
also in degenerative diseases, indicating the key role of induced SC
chronic inflammation in these illnesses (Prattichizzo et al., 2017; Weilner
et al., 2016b). Accordingly, we recently studied the senescence of
endothelial cells (ECs) and the consequent endothelial dysfunction as one
of the main triggers involved not only in the onset and progression of
CVDs but also of other ARDs like osteoporosis (Olivieri et al., 2016), since
ECs are components of the stroma of all tissues and organs (Madonna
et al., 2016; Regina et al., 2016; Prattichizzo et al., 2016; Kirkland and
Tchkonia, 2017).
2. A new era in the field of geroscience: the senotherapeutics
The abovementioned remarks about SC reveal their key role in ARD
and suggest them as potential target. Accordingly, Childs and coworkers3
(2017) have scrupulously reviewed such SC function in ageing and ARD
and evidenced them as potential target for prolonging lifespan and
health-span. Such evidence has started a new era in the field of ger-
oscience thanks to developing the senotherapeutics, drugs affecting (in a
large sense) the senescence process (Olivieri et al., 2016). Senother-
apeutics currently comprises three therapeutic approaches:
I. molecules to selectively kill SC, defined senolytics;
II. compounds able in reducing evocated SC SASP, acting hence as
SASP suppressors, or capable to change the senescent phenotype,
called senomorphics;
III. inhibition of increase of the number of SC in the tissues.
The latter above reported is likely the oldest strategy. Accordingly, a
lot of antioxidants have been demonstrated to postpone the senescence
process in vitro (Bjelakovic et al., 2013). However, the application of
these promising findings, in vivo models (i.e., mice models) by using
traditional antioxidants (e.g., C and E vitamins) have been scarcely
translated in emerging therapies (Bjelakovic et al., 2013). Furthermore,
results from human cohort studies also evidence the incapacity of such
compounds to stop the ARD, even if discordant data have been detected
varying the molecules analyzed (Kirkland and Tchkonia, 2017a). In
contrast, more interesting preclinical findings have been obtained using
senolytics and SASP-suppressing compounds. The senolytics have arisen
using large pharmacological screenings and differential gene expression
studies. In addition, survival pathways have been detected in SC as
senolytics (Kirkland et al., 2017b). Among these, five
anti-apoptotic-pathways (SCAPs) have been discovered and successfully
targeted, including Bcl-family proteins, PI3K-Akt, p53, ephrin-tyrosine
kinases, HIF-1α, and HSP90 pathways (Kirkland et al., 2017). This area
is rapidly growing, and the information offered by using new technolo-
gies, such as single-cell RNAseq, is permitting to provide more insights
into the SC for accelerating the development of new senolytic drugs
(Kirkland et al., 2017b). Remarkably, various pathological phenotypes
related to ageing have been targeted with numerous senolytics in mice
models, such as atherosclerosis. Until now seven classes of compounds
with senolytic activity have been described. Among these, dasatinib,
quercetin, BCL2 family inhibitors, forkhead box protein O4 (FOX-
O4)-interacting peptide blocking the link of FOXO4 with p53, have been
recently reported. In addition, natural compounds, such as fisetin, a
quercetin-related flavonoid, and piperlongumine also show senolytic or
senomorphic action, as well as drugs used for clinical uses targeting the
co-chaperone heat shock protein 90 (HSP90), have recently demon-
strated as an innovative group of senolytics, evocating apoptosis of mu-
rine and human SC in vitro and able to expand healthspan in vivo. For the
end evidence, the FDA-approved histone deacetylase inhibitor, pan-
obinostat, has been considered as senotilic inducing apoptosis of tumor
SC in vitro. Obviously, additional classes of potential senolytics will be
detected thanks to emerging bioinformatic analyses and drug-screening
approaches (Kirkland et al., 2017).
Concerning senomorphics, several classes have also been reported.
Among these, inhibitors of IkB kinase (IKK) and nuclear factor (NF)-kB5,
free radical scavengers and Janus kinase (JAK) pathway inhibitors, as
well as rapamycin able to decrease SASP. Even fisetin has demonstrated
to act with senomorphic impacts on some cell types and with senolytic
effect on others, in vitro.
However, the major number of drugs have been successfully tested in
mice, while have been demonstrated unfavorable for humans, inducing
toxicity (e.g., chemotherapeutics and immunosuppressors). Thus, their
translation to clinical trial testing should be restricted to certain condi-
tions, while an appropriate compound for a whole-population treatment
appears to be far to discover. At present, metformin appears as the most
likely candidate for such use (quoted in Balistreri, 2018). Studies on
model organisms have shown its ability to extend the lifespan (quoted in
Balistreri, 2018), thanks to mechanisms largely debated, including: (a)
the reduced insulin and IGF-1 signaling; (b) the inhibition of mTOR; (c)
Table 1
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inflammation, (e) reducing DNA damage, and (f) the activation of AMPK
(quoted in Balistreri, 2018). Its effect on AMPK have however been
mainly revealed.
3. Senotherapeutics and cardiovascular pathological conditions
related to ageing
Evidence on clearance of SC from the arterial vessels with the aim to
improve the typical age-related vascular phenotypes has led to suggest
that senolytics have the potentiality to reduce cardiovascular patholog-
ical conditions associated with ageing (see Table 1). The tyrosine kinase
inhibitor dasatinib and the flavonoid quercetin have been the first
senolytic drugs to be described as able CVD treatments (Roos et al., 2016;
Xu et al., 2018). However, adverse effects of some drugs have been
recognized (Kirkland et al., 2017b). For instance, the drug navitoclax
(ABT263) with senolytic activity commonly provokes neutropenia and
thrombocytopenia. Senolytic treatments also show other issues. For
example, they can neutralize SC by evocating potentially oncogenic
mutations (Xu et al., 2018). However, mice treated with a combination of
dasatinib and quercetin exhibited increased survival and health span. In
addition, the treatment with dasatinib and quercetin has demonstrated to
improve vasomotor function and to diminish aortic calcification in aged
and hypercholesterolemic mice, respectively, significantly enhancing
cardiac function in aged mice (Zhu et al., 2015; Roos et al., 2016).
Furthermore, stimulation of cardiac progenitor cells in aged hearts and
increased cardiomyocyte proliferative capacity have been described
upon SC removal in aged mice, both using pharmacological approaches
or in genetic senolytic models (Lewis-McDougall et al., 2019). Pharma-
cological and genetic senolytic models have, indeed, shown a connection
between SC diminution, inhibition of heart fibrosis and improved car-
diomyocyte proliferative expression profile (Anderson et al., 2019).
Furthermore, senescent cardiomyocyte elimination via administration of
ABT263 has been observed to improve myocardiac remodeling and the
overall survival rate using a myocardial infarction mouse model
(Walaszczyk et al., 2019). Accordingly, senolytics show the capacity to
reverse phenotypic changes associated with ageing, via reversion of
age-associated cardiac dysfunction and stimulating regenerative capac-
ity, which bolsters senolysis as a potential approach of cardiovascular
pathological conditions (Kirkland and Tchkonia, 2017a; Kirkland et al.,
2017b). In addition, cardiac glycosides have been recently reported as
senolytic compounds, having the strong potential as effective treatments
against these conditions (Guerrero et al., 2019; Triana-Martínez et al.,
2019). The HSP90 chaperone inhibitors have shown the same potential
(Fuhrmann-Stroissnigg et al., 2017), including 17-DMAG able to improve
atherosclerosis in mice (Lazaro et al., 2015), potentially due to its
senolytic activity. Furthermore, 2-deoxy-D-glucose (2DG), a glucose
analog able to inhibits ATP synthesis and determine cell cycle arrest and
cell death, has been found to have senolytic action on senescent vascular
smooth muscle cells. Precisely, 2DG potentially evocates an increased
metabolic activity of SC, which may impact the progression of athero-
sclerosis (Gardner et al., 2015) (see Table 1).
However, the major number of senolytics have been clinically
approved or are already in clinical trials for treating oncologic diseases,
idiopathic pulmonary fibrosis, and chronic kidney disease (Mattison
et al., 2014) studies. Concerning, senolytic drugs in the field of cardio-
vascular conditions, they have only been tested in animal models of
disease, and clinical trials are currently awaited. In alternative via, some
studies have recommended the suppressing of SC as another probable
strategy for cardiovascular disorders. Accordingly, the activation of Sir-
tuin1 (SIRT1) signaling has been consistently described. Precisely, SIRT1
activation mediated by the polyphenol resveratrol has shown to inhibit
both arterial wall inflammation and stiffening in nonhuman primates
(Mattison et al., 2014). Similarly, SIRT1 specific activator SRT1720 re-
duces hypertension and arterial stiffness in mice (Xao et al., 2016)
Important studies have discovered a down-regulated SIRT1 expression in4
vascular smooth cells of patients affected by abdominal aortic aneurysm,
while SIRT1 activation induces inhibition of cell senescence and reduc-
tion of vascular inflammation (Chen et al., 2016). Accordingly, calorie
restriction has been reported to be related to SIRT1 activation in vascular
smooth cells and a reduced prevalence of abdominal aortic aneurysm
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the suppression of VSMC senescence is mediated by SIRT1 signaling
pathways (van der Veer et al., 2007; Imai and Guarente, 2014). Other
proposed clinical treatments are represented by pioglitazone stimulating
telomerase activation and able to reduce the senescence of endothelial
cells (Werner et al., 2011). Unconventional approaches to target SC are
also being examined, including vaccines and other immune modulators,
as well as toxin supply using SC-recognizing technologies. Metformin and
rapamycin (sirolimus) inhibit SASP, reduce the pro-inflammatory milieu
and the damage induced by activated SC (Kirkland and Tchkonia, 2017a)
(see Table 1). Regarding rapamycin, it determines an extension of mice
lifespan, reduces senescence, and shows anti-atherosclerotic effects
(Walters et al., 2016; Evangelisti et al., 2016). Moreover, statins have
been demonstrated to prevent SASP and regulate both the cell cycle and
telomerase (Bennaceur et al., 2014).
Of note are the advances in the development of natural-based
bioactive compounds with potential anti-senescence properties, called
nutraceuticals (Nasri et al., 2014). For instance, polyphenols have anti-
oxidant and anti-inflammatory effects, being possible senostatics by
neutralizing pro-oxidant and pro-inflammatory signaling in SC (Gurau
et al., 2018) Interestingly, another example is resveratrol, indicated as
cell senescence suppressor of cardiovascular complications (Mattison
et al., 2014).
Finally, mesenchymal stem cell (MSC)-based therapies are also re-
ported to counteract senescence-associated cardiovascular conditions
and complications. MSCs are multipotent cells with beneficial actions,
such as multi-differentiation potential and low immunogenicity (Balis-
treri et al., 2020). Clinical trials on MSC transplantation are currently
ongoing, indicating cardiac improvements in cases with heart failure
secondary to ischemic cardiomyopathy (Balistreri et al., 2020).
Contemplating the whole collected evidence on the potential treat-
ments for counteracting age-related cardiovascular conditions, limita-
tions emerge, but a great hope is placed on clinical trials with senolytic
agents. They, by evaluating their safety and efficacy, may lead to further
progresses in developing appropriate patient drug administrations and
offer effective treatments to inhibit the development of SC, associated
pathological conditions and complications.
4. Conclusions
The development of senotherapies for delaying or stopping age-
related cardiovascular conditions is of the great relevance, but
currently shows diverse limitations in its effective clinical application.
Probably, the integration of multi-omics approaches as a promising tool
for their identification might be of help. This idea has derived from the
consideration that current studies have been executed using individual
omics types. This represents a limitation, because the separate omics
evaluations enable the discovery of only a part of such molecules,
reducing the possibility of identifying well-fitted therapies. The analysis
of metabolomics, microbiomic, and nutrigenomic profiles are only just
now emerging, and are leading to the identification of some promising
molecules with anti-senescent effects (Scola et al., 2019). Executing all
the omics analyses can certainly imply the detection of well-fitted ther-
apies in humans, obtaining data from multidimensional levels. A further
help in such research may also be derived from gender medicine that
could add another crucial level in the differential management of car-
diovascular pathologies associated with age and therapies according to
gender. Today, gender represents one of the major challenges in car-
diovascular management and therapies. Having panels of appropriate
senotherapeutic molecules, for the various pathological conditions and
for gender, could also facilitate the design of appropriate algorithms for
their prevention. However, this field of research currently continues to be
young, and consequently needs a major interest and more investigation,
based on more accurate, standardized omics techniques. Nevertheless,
the approaches and techniques developed can give a detailed idea of the
information about detecting innovative treatments (Balistreri, 2018).5
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